Partnering
Unlock therapeutic access of RNAi to all key cell types.
Like a lock to a key, the most proven delivery route for RNAi is ligand-based cell targeting.
Reach farther, faster with receptor-targeted RNA technology.
Our platform for developing receptor-targeted RNA medicines uses advances in deep learning, molecular biology, and high-throughput chemistry to design and validate novel molecules that target extraheptic tissues in vivo within 90 days.
Partner with us to advance your program from target to the clinic:
Accelerated Drug Product & Process Manufacturing
Translational Development to IND
Integrated Drug Discovery & Lead Optimization
Receptome Atlas for Cell-Specific Delivery
AI-powered drug design & delivery platform
Reach more targets, reach more diseases
Our proprietary platform, Connexa, designs RNA therapeutics that can target any cell type, unleashing the full potential of gene silencing in the treatment of chronic diseases
The Connexa Difference
Reach the Right Target
Unlock treatments for conditions of the heart, lungs, kidneys, muscle, small intestine, blood cells, and brain
Using the Right Delivery Vehicle
AI-enabled design of delivery vehicles with all required properties means a rapid and de-risked path to in vivo
With the Right Payload
Maximize efficacy from the start by rationally designing, co-selecting, and
co-optimizing delivery ligands with specific RNA payloads
Partner to create revolutionary RNA medicines
Leverage the only platform built to unlock therapeutic access of RNA to all key cell types.
Let's talk